Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 4,775 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HIV Clear all
Terminated Phase 4 Interventional

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902
View directory record Official record
Conditions
Diabetic Retinopathy, HIV
Interventions
Tesamorelin, Placebo-Control
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

NCT04001803
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA+RPV LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional Results available

A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

NCT03768986
View directory record Official record
Conditions
HIV, HIV Testing, Women, Contingency Management
Interventions
Standard referral for HIV testing, Online risk reduction training, Reinforcement
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 7:21 AM EDT
Terminated Phase 1 Interventional

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431
View directory record Official record
Conditions
Melanoma
Interventions
Poly ICLC, leukapheresis
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional

Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain

NCT02272829
View directory record Official record
Conditions
Opioid Misuse, Older Adults, HIV
Interventions
Choacot: Behavioral Intervention for Chronic Opioid Use, Health Education
Behavioral · Other
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

NCT00000798
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Peptide Vaccine, Microparticulate Monovalent
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

NCT01712256
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vacc-4x
Biological
Lead sponsor
Bionor Immuno AS
Industry
Eligibility
18 Years to 63 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Addressing Psychosocial Needs and HIV Risk in Indian MSM

NCT01266122
View directory record Official record
Conditions
HIV/STI Risk, HIV/STI Incidence
Interventions
Behavioral intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 26, 2026, 7:21 AM EDT
Recruiting Phase 4 Interventional

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335
View directory record Official record
Conditions
HIV, Substance Use Disorder (SUD), Injection Drug Use
Interventions
APRETUDE (cabotegravir)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Youth mHealth Adherence Intervention for HIV+ YMSM

NCT03092115
View directory record Official record
Conditions
HIV
Interventions
HIV medication adherence app
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 24 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418
View directory record Official record
Conditions
HIV Infections
Interventions
gp145 C.6980 Vaccine, Placebo, Aluminum Hydroxide Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 26, 2026, 7:21 AM EDT
Completed No phase listed Observational Results available

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Raltegravir, Dolutegravir, Colonoscopy with biopsy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional Results available

TeleHepC Treatment Trial

NCT04798521
View directory record Official record
Conditions
Hepatitis C
Interventions
Tele-HCV, Community Linkage to Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Roseburg, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 26, 2026, 7:21 AM EDT
Completed No phase listed Observational

Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs

NCT00050908
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NCT00249574
View directory record Official record
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 1 Interventional

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

NCT00002120
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium
Drug
Lead sponsor
U.S. Bioscience
Industry
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 7:21 AM EDT
Not listed Not applicable Interventional

Adherence Intervention for HIV-infected Drug Users

NCT02907697
View directory record Official record
Conditions
HIV, Substance Use
Interventions
Life Steps-Drug Use, General Health Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional

STD Risk Reduction for Heterosexual Methamphetamine Users

NCT00344214
View directory record Official record
Conditions
Substance-Related Disorders, HIV Infections, Sexually Transmitted Diseases
Interventions
Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program, Standard care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

NCT00002387
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurocognitive Effects of Opiate Agonist Treatment

NCT01733693
View directory record Official record
Conditions
Opioid-Related Disorders, HIV, HIV Infections
Interventions
Buprenorphine, Methadone
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 68 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 4 Interventional Results available

Raltegravir Intensification in HIV-infected Patients

NCT00631449
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 26, 2026, 7:21 AM EDT
Completed Phase 2 Interventional Results available

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

NCT00665847
View directory record Official record
Conditions
HIV-1
Interventions
Etravirine (TMC125), Optimized background regimen (OBR)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 26, 2026, 7:21 AM EDT